| ￥3500 | |
| Z05094-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
|
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized BTN3A1/CD277, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiBTN3A1 Antibody, hFc Tag. Test result was comparable to standard batch. | |
| Expression System | HEK293 | |
| Theoretical Molecular Weight | 24.15 kDa | |
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 26-32 kDa based on Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | The three butyrophilin BTN3A molecules, BTN3A1, BTN3A2, and BTN3A3, are members of the B7/butyrophilin-like group of Ig superfamily receptors, which modulate the function of T cells. BTN3A1 controls activation of human Vγ9/Vδ2 T cells by direct or indirect presentation of self and nonself phosphoantigens (pAg). |
| Synonyms | CD277; BTN3A1; BTF5; BT3.1; BTN3.1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
